US2673827A - Therapeutic ion exchange resin mixture - Google Patents

Therapeutic ion exchange resin mixture Download PDF

Info

Publication number
US2673827A
US2673827A US194033A US19403350A US2673827A US 2673827 A US2673827 A US 2673827A US 194033 A US194033 A US 194033A US 19403350 A US19403350 A US 19403350A US 2673827 A US2673827 A US 2673827A
Authority
US
United States
Prior art keywords
exchange resin
sodium
resin
composition
ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US194033A
Inventor
Kenneth G Kohlstaedt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Eli Lilly and Co
Original Assignee
Eli Lilly and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly and Co filed Critical Eli Lilly and Co
Priority to US194033A priority Critical patent/US2673827A/en
Application granted granted Critical
Publication of US2673827A publication Critical patent/US2673827A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J39/00Cation exchange; Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/08Use of material as cation exchangers; Treatment of material for improving the cation exchange properties
    • B01J39/16Organic material
    • B01J39/18Macromolecular compounds
    • B01J39/20Macromolecular compounds obtained by reactions only involving unsaturated carbon-to-carbon bonds

Definitions

  • This invention relates to novel compositions useful in the treatment of edema associated with congestive heart failure, and like disorders.
  • a negative sodium balance and maintenance of a low sodium ion concentration in the body fluids has in the past been obtained either by administering diuretics to prevent renal resorption of sodium, or by the continued ingestion of a diet low in sodium. Both of these methods are disadvantageous.
  • the former method requires frequent injections of a diuretic, which not only are painful but which if long continued may result in severe kidney damage.
  • the latter method requires a strict dietary regime which is unpleasant to the patient and is well-nigh impossible of accomplishment unless the meals permitted by the diet are specially prepared. Accordingly, simpler methods of obtaining a negative sodium balance and maintaining a low sodium uptake are desirable.
  • compositions capable of being taken orally by the patient which composition would 4 Claims. (o1. 167-55) have the ability to combine with the sodium which which is ingested with a normal diet, and largely prevent its retention by the body system.
  • compositions to be usable over long periods of time, must meet a number of requirements.
  • the composition must have a high 03,-! pacity for combining with or fixing sodium ions and a low capacity for fixing the other metal ions which are essential to the well-being of the patient. It must be capable of administration in readily ingestible form. It must be insoluble, or nonabsorbable by the gastrointestinal tract. It must be without unpleasant odor or taste, or have such a mild odor or taste that any unpleasantness may readily be masked by suitable compounding.
  • the composition must be nontoxic, and upon ingestion must produce no gastri'c'distress and no irritation or other untoward effect on the gastric mucosa.
  • compositions which are highly effective in producing and maintaining a low sodium ion concentration in the body despite a normal dietary sodium intake.
  • My compositions comprise a mixture of particular types of ion-exchange resins of uncombined and of salt forms.
  • My invention includes within its scope compositions comprising essentially a mixture of a carboxylic resin in uncombined or acid form, and a carboxylic resin in potassium salt form.
  • compositions comprising a mixture of a carboX- ylic resin in acid and/or ammonium salt form, a carboxylic resin in potassium salt form, and an anion exchange resin in uncombined or basic form.
  • mixtures comprising the carboxylic resin in potassium salt, and acid salt form will hereafter be referred to as binary compositions, and those inclusive of the anion resin will be termed ternary compositions.
  • Binary compositions suitable for therapeutic administration range in ther make-up from about one part of the potassium salt form of the resin and four parts of the acid form ofthe resin, to about one part of the potassium salt form and one part of the acid form of the resin.
  • compositions comprising one part of the potassium salt form, and two parts of the acid form of the resin is desirable.
  • an amount which can range up to about one part (with reference to the amount of potassium salt form) of an anion exchange resin.
  • the binary mixtures of this invention are useful in short term treatment and in those cases where the patient has a good renal function and has sufiered no impairment in his ability to produce ammonia in the kidneys. In such cases any tendency toward acidosis resulting from ingestion of the resin mixture is offset by the ability of the kidney to produce ammonia. for combination with and elimination of chloride and other anions.
  • the acid-producing qualities of the carboxylic acid resin can be offset to an extent by employment of the resin in its ammonium salt form. This is but a partial solution of the problem, however, as the anion (commonly the chloride ion) remaining after removal of the sodium cation is in its effect in the body an acidic ion, and requires removal.
  • Means of removing the chloride ion (or other acidic anions) is provided in the ternary compositions of this invention by the inclusion therein of the anion exchange resin.
  • the addition of the anion exchange resin not only prevents the development of an acidosis in the patient under treatment, but also appears to increase the efficiency of the carboxylic resin so that a more effective removal of sodium is obtained.
  • the amount of anion exchange resin employed in the compositions is in part controlled bythe degree of renal impairment in the patient and by the relative amount of the acid form of the carbo xylic resin in the composition, greater amounts of anion exchange resin being preferred in compositions containing a large proportion of acid carboxylic resin, and/or appreciable renal impairment.
  • My novel compositions are prepared by a mixing together of the ion exchange resins in the proportions required for the particular composition desired.
  • the acid, and the potassium forms of the carboxylic resin can be of the same or different resins.
  • the resins being powders need no further processing to make them cap-able of oral ingestion, a simple mixing being sufiicient.
  • carboxylic ion-exchange resins can be employed in the preparation of compositions of the above character.
  • car boxylic acid resins sold by Robin and Haas under the names Amberlite XE-64 and IRS-50 are satisfactory.
  • the resins are available inthe acid form only.
  • any of the usual and known procedures for converting acid resins into their salt forms can be used, as for example, treating the acid resin with a solution of potassium hydroxide, anddrying the resin salt thus produced.
  • anion exchange resins can be employed in the preparation of the compositions of this invention.
  • polyamine and quaternary ammonium typeresins can be employed.
  • Resins found to be quite acceptable for the purposes of this invention are those of the character described in United States Patent No. 2,402,384, issued June 18, 1948.
  • a resin of the type disclosed in the patent is that sold by Rohm and Haas under the'name Amberlite XE-58.
  • compositions of this invention are so effective in adsorbing the sodium ions present in the gastrointestinal tract, for past 4 experience with carboxylic resins has demon strated their inability to fix appreciable amounts of sodium ions in the acid and alkaline ranges existing within the gastrointestinal tract. It is further surprising, but an observed fact, that the mixtures of resins employed herein apparently exhibit within the body a peculiar tendency to adsorb sodium ions in preference to other ions so that continued ingestion of the compositions of this invention does not deplete the body of other essential metal ions as might be expected. Inlong-term clinical trials of the compositions of this invention, careful analyses conducted upon blood samples has, failed to detect any depletion of essential metal ions.
  • compositions within the scope of this invention are as follows, the proportions being expressed in parts by weight:
  • composition A Parts Amberlite XE-64 (acid form) 2 Amberlite XE-fiel (potassium salt form) 1
  • a composition prepared in accordance with the above formula when administered in amount of about 30 to 50 g. per day, maintains a low sodium concentration in the body fluids in a patient ingesting a normal diet, '(kllli; is, a diet which will supply about 3 g. of sodium per day.
  • composition 13 Parts Amberlite Kid-64 (acid form) i Amber-lite XE-fii (potassium salt form) 1
  • a composition of the above character is especially suitable for treating patients having an impaired renal function.
  • the composition When administered in an amount of about 25 to 35 g. per day will maintain a low sodium concentration in the body fluids and will leave the concentrations of the other essential metals substantially unchanged.
  • composition C Parts Amberlite- XE-Ei l (acid form) 1 Amberlite XE-64 (potassium salt form) 1
  • the above composition administered in amounts of about 30 to 40 g. per day provides excellent control; of sodium concentration in patients having an unimpaired renal function.
  • the relatively large amount of potassium present in the above composition not only serves in itself to displace sodium, but in addition, acts as a diuretic, and in so acting serves to provide renal clearance for additional sodium.
  • a composition containing a relatively large amount of potassium as does the above illustrative example, is especially suitable for providing a rapid decrease in the sodium content of the body fluids.
  • composition D Parts Amberl1te XE-54 (acid form) 5 Amberlite XE-(S i (potassium salt form) 2.5 "Amberlite XE-58 1
  • Theabove composition administered in aqueous suspension in the amount of about 40 to 7 (1" g. per day (depending upon the amount of dietary sodium) provides an excellent control of sodium concentration, and can be administered to pa tients having extensive renal damage over long periods of time without depletion of essential ions or production of any observable metabolic imgla A onion.
  • the dispersibility of the above composition in water is improved by incorporation of a dispers- For example Tween 80 is intimately mixed with the anion exchange resin in the amount of about 0.5 percent by weight, prior to the mixing of the resin powders.
  • a dispers- For example Tween 80 is intimately mixed with the anion exchange resin in the amount of about 0.5 percent by weight, prior to the mixing of the resin powders.
  • compositions which are in the form of dry powders, are made readily ingestible their suspension in water.
  • aqueous simple suspensions which settle out rapidly, more stable and permanent suspensions are prepared by mixing the powder with an aqueous solution of a thickening agent, for example, methyl cellulose or acacia.
  • the suspension can be further stabilized by the addition of a substantially nontoxic, nonionic, emulsifying agent. Paiatability of the above compositions can be increased by the addition of suitable flavoring agents.
  • the method of converting the acid form of a resin into the potassium salt form is illustrated by the following conversion of acid Amberlite XE-64 into its potassium salt form.
  • a therapeutically effective ion-exchange resin composition adapted for the removal of sodium ions from the gastrointestinal tract, said composition being substantially free from sodium,
  • a therapeutically efiective ion-exchange resin composition adapted for the removal of sodiuin ions from the gastrointestinal tract, said composition being substantially free from sodium, and comprising essentially about one part of the potassium salt form of a carboxylic ion-exchange resin and about two parts of a carboxylic ion-exchange resin in acid form.
  • a therapeutically efiective ion-exchange resin composition adapted for the removal of sodium ions from the gastrointestinal tract, said composition being substantially free from sodium, and comprising essentially about one part of a carboxylic ion-exchange resin in potassium salt form, about one to about four parts of a carboxylic ion-exchange resin in acid form, and an amount up to about one part of an anion exchange resin.
  • a therapeutically efiective ion-exchange resin composition adapted for the removal of sodium ions from the gastrointestinal tract, said composition being substantially free from sodium, and comprising about two and one half parts of a carboxylic ion-exchange resin in potassium salt form, about five parts of a carboxylic ion-exchange resin in acid form, and about one part of an anion exchange resin.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Description

Patented Mar. 30, 1954 THERAPEUTIC ION EXCHANGE RESIN MIXTURE Kennetlr G. Kohlstaedt, Indianapolis, Ind., as-
signor'to Eli Lilly and Company, Indianapolis, Ind., a'corporation of Indiana No Drawing. Application November 3, 1950, Serial No. 194,033
This is a continuation-in-part of United States patent application Serial No. 156,508, filed April 17, 1950, now abandoned.
This invention relates to novel compositions useful in the treatment of edema associated with congestive heart failure, and like disorders.
In certain edematous conditions it has long been the practice to establish a negative sodium balance in the afilicted patient to decrease the concentration of sodium in extracellular space, thus producing a lower blood volume and minimizing the tendency toward edema or distressing ascites. Also, as is well known, the establishment of a low sodium concentration is desirable in cases of hypertension, to reduce arterial blood pressure.
A negative sodium balance and maintenance of a low sodium ion concentration in the body fluids has in the past been obtained either by administering diuretics to prevent renal resorption of sodium, or by the continued ingestion of a diet low in sodium. Both of these methods are disadvantageous. The former method requires frequent injections of a diuretic, which not only are painful but which if long continued may result in severe kidney damage. The latter method requires a strict dietary regime which is unpleasant to the patient and is well-nigh impossible of accomplishment unless the meals permitted by the diet are specially prepared. Accordingly, simpler methods of obtaining a negative sodium balance and maintaining a low sodium uptake are desirable.
From the standpoint of convenience of administration, one of the simplest methods of establishing a negative sodium balance would be to provide a composition capable of being taken orally by the patient, which composition would 4 Claims. (o1. 167-55) have the ability to combine with the sodium which which is ingested with a normal diet, and largely prevent its retention by the body system.
Such a composition, to be usable over long periods of time, must meet a number of requirements. The composition must havea high 03,-! pacity for combining with or fixing sodium ions and a low capacity for fixing the other metal ions which are essential to the well-being of the patient. It must be capable of administration in readily ingestible form. It must be insoluble, or nonabsorbable by the gastrointestinal tract. It must be without unpleasant odor or taste, or have such a mild odor or taste that any unpleasantness may readily be masked by suitable compounding. The composition must be nontoxic, and upon ingestion must produce no gastri'c'distress and no irritation or other untoward effect on the gastric mucosa.
In a search for a composition meeting the ,above requirements, it has recently been proirritating to the intestinal mucosa and causegastric pains. Moreover, they adsorb or fix all metal ions indiscriminately, so that after a relatively short time the treated subject suffers from the depletion of calcium, potassium and other metals essential to health.
I have discovered novel compositions which are highly effective in producing and maintaining a low sodium ion concentration in the body despite a normal dietary sodium intake. My compositions comprise a mixture of particular types of ion-exchange resins of uncombined and of salt forms. My invention includes within its scope compositions comprising essentially a mixture of a carboxylic resin in uncombined or acid form, and a carboxylic resin in potassium salt form. Also included within the scope of my invention as preferred embodiments thereof are compositions comprising a mixture of a carboX- ylic resin in acid and/or ammonium salt form, a carboxylic resin in potassium salt form, and an anion exchange resin in uncombined or basic form. For convenience, mixtures comprising the carboxylic resin in potassium salt, and acid salt form will hereafter be referred to as binary compositions, and those inclusive of the anion resin will be termed ternary compositions.
Binary compositions suitable for therapeutic administration range in ther make-up from about one part of the potassium salt form of the resin and four parts of the acid form ofthe resin, to about one part of the potassium salt form and one part of the acid form of the resin.
For most purposes, a composition comprising one part of the potassium salt form, and two parts of the acid form of the resin is desirable. In the preferred ternary compositions there is incorporated in the above binary mixtures an amount which can range up to about one part (with reference to the amount of potassium salt form) of an anion exchange resin.
The binary mixtures of this invention are useful in short term treatment and in those cases wherethe patient has a good renal function and has sufiered no impairment in his ability to produce ammonia in the kidneys. In such cases any tendency toward acidosis resulting from ingestion of the resin mixture is offset by the ability of the kidney to produce ammonia. for combination with and elimination of chloride and other anions. The acid-producing qualities of the carboxylic acid resin can be offset to an extent by employment of the resin in its ammonium salt form. This is but a partial solution of the problem, however, as the anion (commonly the chloride ion) remaining after removal of the sodium cation is in its effect in the body an acidic ion, and requires removal. Means of removing the chloride ion (or other acidic anions) is provided in the ternary compositions of this invention by the inclusion therein of the anion exchange resin. The addition of the anion exchange resin not only prevents the development of an acidosis in the patient under treatment, but also appears to increase the efficiency of the carboxylic resin so that a more effective removal of sodium is obtained. The amount of anion exchange resin employed in the compositions is in part controlled bythe degree of renal impairment in the patient and by the relative amount of the acid form of the carbo xylic resin in the composition, greater amounts of anion exchange resin being preferred in compositions containing a large proportion of acid carboxylic resin, and/or appreciable renal impairment.
My novel compositions are prepared by a mixing together of the ion exchange resins in the proportions required for the particular composition desired. The acid, and the potassium forms of the carboxylic resin can be of the same or different resins. The resins being powders need no further processing to make them cap-able of oral ingestion, a simple mixing being sufiicient. However, because the resins are most readily ingested when in the form of aqueous suspensions, it is desirable to have the resins in finely powdered form and to incorporate in the mixture a small amount of wetting agent to assist in obtaining a ready dispersion of the powder in water.
Various carboxylic ion-exchange resins can be employed in the preparation of compositions of the above character. Thusfor example, the car boxylic acid resins sold by Robin and Haas under the names Amberlite XE-64 and IRS-50 are satisfactory. Other carboxylic resins, for example that sold by Permutit Company under the name Permutit XAC, are also suitable. Generally, the resins are available inthe acid form only. To provide the potassium salt or the ammonium salt form used in compounding the compositions of this invention, any of the usual and known procedures for converting acid resins into their salt forms can be used, as for example, treating the acid resin with a solution of potassium hydroxide, anddrying the resin salt thus produced.
A variety of anion exchange resins can be employed in the preparation of the compositions of this invention. Thus for example; both polyamine and quaternary ammonium typeresins can be employed. Resins found to be quite acceptable for the purposes of this invention are those of the character described in United States Patent No. 2,402,384, issued June 18, 1948. A resin of the type disclosed in the patent is that sold by Rohm and Haas under the'name Amberlite XE-58.
It is surprising that the compositions of this invention are so effective in adsorbing the sodium ions present in the gastrointestinal tract, for past 4 experience with carboxylic resins has demon strated their inability to fix appreciable amounts of sodium ions in the acid and alkaline ranges existing within the gastrointestinal tract. It is further surprising, but an observed fact, that the mixtures of resins employed herein apparently exhibit within the body a peculiar tendency to adsorb sodium ions in preference to other ions so that continued ingestion of the compositions of this invention does not deplete the body of other essential metal ions as might be expected. Inlong-term clinical trials of the compositions of this invention, careful analyses conducted upon blood samples has, failed to detect any depletion of essential metal ions.
Illustrative compositions within the scope of this invention are as follows, the proportions being expressed in parts by weight:
Composition A Parts Amberlite XE-64 (acid form) 2 Amberlite XE-fiel (potassium salt form) 1 A composition prepared in accordance with the above formula, when administered in amount of about 30 to 50 g. per day, maintains a low sodium concentration in the body fluids in a patient ingesting a normal diet, '(kllli; is, a diet which will supply about 3 g. of sodium per day.
Composition 13 Parts Amberlite Kid-64 (acid form) i Amber-lite XE-fii (potassium salt form) 1 A composition of the above character is especially suitable for treating patients having an impaired renal function. The composition When administered in an amount of about 25 to 35 g. per day will maintain a low sodium concentration in the body fluids and will leave the concentrations of the other essential metals substantially unchanged.
Composition C Parts Amberlite- XE-Ei l (acid form) 1 Amberlite XE-64 (potassium salt form) 1 The above composition administered in amounts of about 30 to 40 g. per day provides excellent control; of sodium concentration in patients having an unimpaired renal function. The relatively large amount of potassium present in the above composition not only serves in itself to displace sodium, but in addition, acts as a diuretic, and in so acting serves to provide renal clearance for additional sodium. A composition containing a relatively large amount of potassium as does the above illustrative example, is especially suitable for providing a rapid decrease in the sodium content of the body fluids.
Composition D Parts Amberl1te XE-54 (acid form) 5 Amberlite XE-(S i (potassium salt form) 2.5 "Amberlite XE-58 1 Theabove composition administered in aqueous suspension in the amount of about 40 to 7 (1" g. per day (depending upon the amount of dietary sodium) provides an excellent control of sodium concentration, and can be administered to pa tients having extensive renal damage over long periods of time without depletion of essential ions or production of any observable metabolic imgla A onion.
ing agent in the above mixture.
The dispersibility of the above composition in water is improved by incorporation of a dispers- For example Tween 80 is intimately mixed with the anion exchange resin in the amount of about 0.5 percent by weight, prior to the mixing of the resin powders.
The above illustrative compositions, which are in the form of dry powders, are made readily ingestible their suspension in water. In place of aqueous simple suspensions which settle out rapidly, more stable and permanent suspensions are prepared by mixing the powder with an aqueous solution of a thickening agent, for example, methyl cellulose or acacia. The suspension can be further stabilized by the addition of a substantially nontoxic, nonionic, emulsifying agent. Paiatability of the above compositions can be increased by the addition of suitable flavoring agents.
The method of converting the acid form of a resin into the potassium salt form is illustrated by the following conversion of acid Amberlite XE-64 into its potassium salt form.
To 5 /2 pounds of the acid form of Amberlite XE-E is added a solution of 1850 g. of potassium hydroxide in 16 liters of water. The mixture is allowed to stand for about 24 hours, with occasional stirring. The mixture is diluted with an equal volume of distilled water, is filtered, and the residue consisting of the resin in potassium salt form is washed thoroughly with distilled water. The moist precipitate of potassium resin is dried at 60 C. in vacuo.
I claim:
1. A therapeutically effective ion-exchange resin composition adapted for the removal of sodium ions from the gastrointestinal tract, said composition being substantially free from sodium,
and comprising essentially about one part of the potassium salt form of a oarboxylic ion-exchange resin, and from about one to about four parts of a carboxylic ion-exchange resin in acid form.
2. A therapeutically efiective ion-exchange resin composition adapted for the removal of sodiuin ions from the gastrointestinal tract, said composition being substantially free from sodium, and comprising essentially about one part of the potassium salt form of a carboxylic ion-exchange resin and about two parts of a carboxylic ion-exchange resin in acid form.
3. A therapeutically efiective ion-exchange resin composition adapted for the removal of sodium ions from the gastrointestinal tract, said composition being substantially free from sodium, and comprising essentially about one part of a carboxylic ion-exchange resin in potassium salt form, about one to about four parts of a carboxylic ion-exchange resin in acid form, and an amount up to about one part of an anion exchange resin.
4. A therapeutically efiective ion-exchange resin composition adapted for the removal of sodium ions from the gastrointestinal tract, said composition being substantially free from sodium, and comprising about two and one half parts of a carboxylic ion-exchange resin in potassium salt form, about five parts of a carboxylic ion-exchange resin in acid form, and about one part of an anion exchange resin.
KENNETH G. KOHLSTAEDT.
References Cited in the his of this patent UNITED STATES PATENTS Number Name Date 2,409,861 Hunter Oct. 22, 1946 2,531,035 Martin Jan. 1, 1952 OTHER REFERENCES volume 6, April 28, November 1949, pages 1493 to 1411.
Amberlite, IRC-50, April 1948 (9 pages), Rohm and Haas Company, Philadelphia, Pa.
Kunin, Analytical Chemistry, January 1949, pages 87 to 96.
Kunin, Industrial & Engineering Chemistry, June 1949, pages 1265 to 1272.

Claims (1)

1. A THERAPUETICALLY EFFECTIVE ION-EXCHANGE RESIN COMPOSITION ADAPTED FOR THE REMOVAL OF SODIUM IONS FROM THE GASTROINTESTINAL TRACT, SAID COMPOSITION BEING SUBSTANTIALLY FREE FROM SODIUM, AND COMPRISING ESSENTIALLY ABOUT ONE PART OF THE POTASSIUM SALT FORM OF A CARBOXYLIC ION-EXCHANGE RESIN, AND FROM ABOUT ONE TO ABOUT FOUR PARTS OF A CARBOXYLIC ION-EXCHANGE RESIN IN ACID FORM.
US194033A 1950-11-03 1950-11-03 Therapeutic ion exchange resin mixture Expired - Lifetime US2673827A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US194033A US2673827A (en) 1950-11-03 1950-11-03 Therapeutic ion exchange resin mixture

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US194033A US2673827A (en) 1950-11-03 1950-11-03 Therapeutic ion exchange resin mixture

Publications (1)

Publication Number Publication Date
US2673827A true US2673827A (en) 1954-03-30

Family

ID=22716032

Family Applications (1)

Application Number Title Priority Date Filing Date
US194033A Expired - Lifetime US2673827A (en) 1950-11-03 1950-11-03 Therapeutic ion exchange resin mixture

Country Status (1)

Country Link
US (1) US2673827A (en)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2823163A (en) * 1956-10-11 1958-02-11 Richard K Thoms Antivaginitis process and cation exchange resin composition
US2987441A (en) * 1958-11-14 1961-06-06 Horner Frank W Ltd Debittering anion-exchange resin particle surfaces of penicillin anions, and tasteless resin particles of penicillin
US3003920A (en) * 1956-08-02 1961-10-10 William E Dominick Chewing gum preparation
US3035979A (en) * 1959-04-15 1962-05-22 Wallace & Tiernan Inc Pharmaceutical composition containing a resin-narcotic compound and a resinantihistamine compound
US3070508A (en) * 1959-06-10 1962-12-25 Merck & Co Inc Method for rendering nicotinamide palatable
US3084099A (en) * 1958-08-04 1963-04-02 Wallace & Tiernan Inc Therapeutic amine-resin complex composition and method of using same
US3269911A (en) * 1962-06-14 1966-08-30 Jefferson Medical College Restoration of blood to biochemical normalcy by treatment with ion exchange resins
US3383281A (en) * 1961-09-22 1968-05-14 Merck & Co Inc Method for binding bile acids in vivo

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409861A (en) * 1942-02-02 1946-10-22 Dow Chemical Co Process and agents for the recovery of magnesium ions from brine
US2581035A (en) * 1949-03-26 1952-01-01 Nat Drug Co Anion exchange resin antacid

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2409861A (en) * 1942-02-02 1946-10-22 Dow Chemical Co Process and agents for the recovery of magnesium ions from brine
US2581035A (en) * 1949-03-26 1952-01-01 Nat Drug Co Anion exchange resin antacid

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3003920A (en) * 1956-08-02 1961-10-10 William E Dominick Chewing gum preparation
US2823163A (en) * 1956-10-11 1958-02-11 Richard K Thoms Antivaginitis process and cation exchange resin composition
US3084099A (en) * 1958-08-04 1963-04-02 Wallace & Tiernan Inc Therapeutic amine-resin complex composition and method of using same
US2987441A (en) * 1958-11-14 1961-06-06 Horner Frank W Ltd Debittering anion-exchange resin particle surfaces of penicillin anions, and tasteless resin particles of penicillin
US3035979A (en) * 1959-04-15 1962-05-22 Wallace & Tiernan Inc Pharmaceutical composition containing a resin-narcotic compound and a resinantihistamine compound
US3070508A (en) * 1959-06-10 1962-12-25 Merck & Co Inc Method for rendering nicotinamide palatable
US3383281A (en) * 1961-09-22 1968-05-14 Merck & Co Inc Method for binding bile acids in vivo
US3269911A (en) * 1962-06-14 1966-08-30 Jefferson Medical College Restoration of blood to biochemical normalcy by treatment with ion exchange resins

Similar Documents

Publication Publication Date Title
CA1117013A (en) Method for treating kidney stones
US4405596A (en) Pharmaceutical preparations for and treatment procedures involving increasing plasma bicarbonate level
JPS5838421B2 (en) Ornithine and arginine salts of branched keto acids and their use in the treatment of liver and kidney disorders
US2673827A (en) Therapeutic ion exchange resin mixture
US2477080A (en) Antacid preparation
AU602899B2 (en) Treatment of hypertension, compounds and compositions for antihypertension and diuresis
JPH04159223A (en) Emetocathartic composition
EP0150792B1 (en) Drugs and the use of poorly soluble compounds of calcium and/or magnesium for the production of drugs
JPS625975A (en) Flocemide derivative
US4098883A (en) Aluminum compound and pharmaceutical compositions containing same
US20040106678A1 (en) Compositions for the parenteral administration of calcium and magnesium
US3070508A (en) Method for rendering nicotinamide palatable
JPH0563452B2 (en)
US2781290A (en) Therapeutic cation exchange resin composition
US3066073A (en) Antacid:calcium phosphate gelmagnesium trisilicate
JPH0579648B2 (en)
US4960591A (en) Methods and compositions for relief of stomach distress
DE3814856C2 (en)
JPS6229526A (en) Remedy and preventive for hypercalciuria
US2260870A (en) Medicinal preparation
US3055805A (en) Process of treating acidosis with t.h.a.m.
US2192386A (en) Insulin preparation and process
US3322767A (en) Tham salts
US3164519A (en) Antacid composition and method of using same
Carroll et al. Renal tubular acidosis presenting with muscle weakness